IGC Pharma (NYSEAMERICAN:IGC) Shares Cross Above 200-Day Moving Average of $0.00

IGC Pharma, Inc. (NYSEAMERICAN:IGC)’s stock price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.00 and traded as high as $0.33. IGC Pharma shares last traded at $0.32, with a volume of 132,947 shares changing hands.

IGC Pharma Trading Down 2.4 %

The company has a debt-to-equity ratio of 0.01, a current ratio of 2.38 and a quick ratio of 1.14. The stock has a market cap of $17.19 million, a PE ratio of -1.52 and a beta of 1.73.

IGC Pharma (NYSEAMERICAN:IGC) last issued its earnings results on Thursday, August 10th. The construction company reported ($0.04) earnings per share (EPS) for the quarter. The firm had revenue of $0.56 million during the quarter. IGC Pharma had a negative net margin of 860.24% and a negative return on equity of 64.87%.

Institutional Trading of IGC Pharma

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Commonwealth Equity Services LLC raised its stake in shares of IGC Pharma by 211.3% during the 3rd quarter. Commonwealth Equity Services LLC now owns 165,490 shares of the construction company’s stock valued at $59,000 after purchasing an additional 112,334 shares during the period. Renaissance Technologies LLC increased its stake in IGC Pharma by 47.5% in the 2nd quarter. Renaissance Technologies LLC now owns 162,709 shares of the construction company’s stock worth $51,000 after acquiring an additional 52,409 shares during the last quarter. Millennium Management LLC increased its stake in IGC Pharma by 76.2% in the 4th quarter. Millennium Management LLC now owns 144,724 shares of the construction company’s stock worth $46,000 after acquiring an additional 62,599 shares during the last quarter. Jane Street Group LLC increased its stake in IGC Pharma by 302.6% in the 2nd quarter. Jane Street Group LLC now owns 48,281 shares of the construction company’s stock worth $26,000 after acquiring an additional 36,290 shares during the last quarter. Finally, Vident Investment Advisory LLC increased its stake in IGC Pharma by 66.3% in the 1st quarter. Vident Investment Advisory LLC now owns 104,011 shares of the construction company’s stock worth $99,000 after acquiring an additional 41,457 shares during the last quarter. 4.92% of the stock is currently owned by institutional investors.

IGC Pharma Company Profile

IGC Pharma, Inc, a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development.